பூர்ணா பெண் சுகாதாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பூர்ணா பெண் சுகாதாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பூர்ணா பெண் சுகாதாரம் Today - Breaking & Trending Today

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead
Hyloris Pharmaceuticals SAAugust 4, 2021 GMT
On target to grow the broad product pipeline with at least 3 additional programmes before end 2021
Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV
Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end
€53.47 million in cash and cash equivalents to execute ambitious growth strategy
Conference call and webcast today at 3pm CEST/9am EST (details below)
Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month p ....

United States , United Kingdom , Marieke Vermeersch , Stijn Van Rompay , Miconazole Domiphen , Olivier Declercq , Chris Buyse , Alter Pharma Group For Maxigesic , Alter Pharma Group , International Standard On Review Engagements , Hyloris Pharmaceuticals , Company Group Structure , Hyloris Pharmaceuticals Sa Euronext Brussels , Corporate Communications , Pharma Bavaria International , Hikma Pharmaceuticals , Euronext Brussels , Van Rompay , Chief Executive Officer , South America , Latin America , Purna Female Healthcare , Miconazole Domiphen Bromide , Tranexamic Acid , Fusidic Acid , Alter Pharma ,

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results
On track to fuel the pipeline with =4 new product candidates in 2021
Strong cash position of €64 million year-end to execute ambitious growth plan
14 commercial products expected by 2024
Conference call and
Liège, Belgium - 9 March 2021 -
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented:
I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our kno ....

United States , Hong Kong , United Kingdom , Czech Republic , Region Flamande , United Arab Emirates , Abuz Aby , New Zealand , Amber Fennell , Van Rompay , Kensington Pharma , Biocapital Europe , Olivier Declercq , Chris Welsh , Marc Foidart , Marieke Vermeersch , Carolyn Myers , Stijn Van Rompay , Ted Maloney , Chris Buyse , Lucy Featherstone , National Marketing Authorizations , University Of Antwerp Belgium , European Union , Kempen Life Sciences Conference , Hyloris Pharmaceuticals ,

Hyloris and Purna Female Healthcare announce partnership to develop novel women's health product

T: +44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialised through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company s wider portfolio with a focus on intravenous cardio ....

Region Flamande , Gilbert Donders , Chris Welsh , Bart Peeters , Amber Fennell , Marieke Vermeersch , Stijn Van Rompay , Ruyck Soares , Hyloris Pharmaceuticals , Antwerp University Hospital , Global Info Research , Purna Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , University Of Antwerp Belgium , Corporate Communications , University Of Antwerp , Consilium Strategic Communications , Purna Female Healthcare , Euronext Brussels , Domiphen Bromide , Female Healthcare , Van Rompay , Chief Executive Officer , Managing Director , Key Opinion Leader , Chief Executive ,